Clinical Trials Browser

Phase 1 × INDUSTRY × RO6839921 × Clear all

NCT02098967 2018-05-17

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms

NCT01677780 2017-07-07

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Phase 1 Completed

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Neoplasms